title: Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient.
abstract: The rate of infection in patients who require ventricular assist devices is estimated at more than 35%. Infections with multi-resistant organisms such as methicillin-resistant Staphylococcus aureus in ventricular assist device recipients are often difficult to treat and present a high mortality rate. Daptomycin is a new cyclic lipopeptide antibiotic, useful in gram-positive organisms resistant to standard treatment. We report a case of a 65-year-old man suffering from a dilatative cardiomyopathy and concomitant MRSA infection who received a biventricular assist device. The patient had MRSA sepsis develop resistant to conventional therapy, which was successfully treated with daptomycin.
authors.affiliation: Department of Anesthesiology, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany. florian.weis@med.uni-muenchen.de
authors.forename: Florian
authors.initials: F
authors.lastname: Weis
authors.forename: Andres
authors.initials: A
authors.lastname: Beiras-Fernandez
authors.forename: Ingo
authors.initials: I
authors.lastname: Kaczmarek
authors.forename: Ralf
authors.initials: R
authors.lastname: Sodian
authors.forename: Calin
authors.initials: C
authors.lastname: Vicol
authors.forename: Bruno
authors.initials: B
authors.lastname: Reichart
authors.forename: Marion
authors.initials: M
authors.lastname: Weis
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy*; D017576:Daptomycin / Q000627:therapeutic use*; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology; D013211:Staphylococcus aureus / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin